|Bid||0.7600 x 165000|
|Ask||0.7950 x 165000|
|Day's Range||0.7600 - 0.7600|
|52 Week Range||0.1750 - 8.2950|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
ReWalk Robotics is soaring after the manufacturer of robotic medical devices with lower limb disabilities announced that the FDA has cleared its exosuit for sale. It is the only suit with FDA clearance. Yahoo Finance's Jared Blikre join Seana Smith.
ReWalk (RWLK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stock futures extended a new strong market rally, Salesforce, Pivotal Software, Ambarella were big movers on earnings. ReWalk Robotics stock nearly tripled after the FDA OK'd its exo-suit.
The Yokneam Ilit, Israel-based company said it had a loss of $1.25 per share. The maker of wearable robotic exoskeletons that help paralyzed patients walk posted revenue of $1.6 million in the period. ...
ReWalk said a Cigna Corp (NYSE: CI) insurance beneficiary in New York became eligible to receive its ReWalk Personal 6.0 exoskeleton. The person had suffered a spinal cord injury in a motorcycle accident in 2016. Cigna revised its policy regarding coverage of exoskeleton medical devices for persons with spinal cord injury in February after having a non-coverage policy previously.